Quick Answer
Candel Therapeutics, Inc. reported Net Income of -$38.18 million for fiscal year 2025.
Candel Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$38.18M | +30.8% |
| 2024 | -$55.18M | -45.4% |
| 2023 | -$37.94M | -101.9% |
| 2022 | -$18.79M | +48.0% |
| 2021 | -$36.12M | -104.3% |
| 2020 | -$17.68M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$11.27M | -5.9% | -135.0% |
| June 30, 2025 | -$4.80M | +78.4% | -165.0% |
| March 31, 2025 | $7.38M | +189.8% | +169.3% |
| September 30, 2024 | -$10.65M | -26.2% | +52.1% |
| June 30, 2024 | -$22.24M | -131.3% | -170.5% |
| March 31, 2024 | -$8.22M | +6.5% | +2.5% |
| September 30, 2023 | -$8.44M | +2.9% | +12.3% |
| June 30, 2023 | -$9.61M | -131.7% | -9.3% |
- Candel Therapeutics, Inc. showed an increase of +30.8% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Candel Therapeutics, Inc.’s net income has declined by 116.0% (from -$17.68 million to -$38.18 million).
- The most recent figure is from Candel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: